JP2019535754A5 - - Google Patents

Download PDF

Info

Publication number
JP2019535754A5
JP2019535754A5 JP2019527426A JP2019527426A JP2019535754A5 JP 2019535754 A5 JP2019535754 A5 JP 2019535754A5 JP 2019527426 A JP2019527426 A JP 2019527426A JP 2019527426 A JP2019527426 A JP 2019527426A JP 2019535754 A5 JP2019535754 A5 JP 2019535754A5
Authority
JP
Japan
Prior art keywords
formula
compound according
compound
pharmaceutically acceptable
equation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019527426A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535754A (ja
JP7167021B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/063182 external-priority patent/WO2018098390A1/en
Publication of JP2019535754A publication Critical patent/JP2019535754A/ja
Publication of JP2019535754A5 publication Critical patent/JP2019535754A5/ja
Application granted granted Critical
Publication of JP7167021B2 publication Critical patent/JP7167021B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019527426A 2016-11-23 2017-11-24 アルブミン結合psma阻害剤 Active JP7167021B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662425810P 2016-11-23 2016-11-23
US62/425,810 2016-11-23
PCT/US2017/063182 WO2018098390A1 (en) 2016-11-23 2017-11-24 Albumin-binding psma inhibitors

Publications (3)

Publication Number Publication Date
JP2019535754A JP2019535754A (ja) 2019-12-12
JP2019535754A5 true JP2019535754A5 (enExample) 2021-01-07
JP7167021B2 JP7167021B2 (ja) 2022-11-08

Family

ID=60812130

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019527426A Active JP7167021B2 (ja) 2016-11-23 2017-11-24 アルブミン結合psma阻害剤

Country Status (8)

Country Link
US (1) US11147889B2 (enExample)
EP (1) EP3544960A1 (enExample)
JP (1) JP7167021B2 (enExample)
CN (1) CN109982998A (enExample)
BR (1) BR112019010206A2 (enExample)
CA (1) CA3043619A1 (enExample)
MX (1) MX2019005742A (enExample)
WO (1) WO2018098390A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200339625A1 (en) * 2017-10-22 2020-10-29 Provincial Health Services Authority Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer
US20210276971A1 (en) * 2018-06-20 2021-09-09 The Research Foundation For The State University Of New York Triazamacrocycle-derived chelator compositions for coordination of imaging and therapy metal ions and methods of using same
US20220009883A1 (en) * 2018-11-14 2022-01-13 Noria Therapeutics, Inc. Thioamide-containing compositions and methods of use thereof
WO2020108753A1 (en) * 2018-11-28 2020-06-04 ITM Isotopen Technologien München AG Novel tumor antigen binding agents and uses thereof
US12472272B2 (en) 2019-04-17 2025-11-18 Provincial Health Services Authority Radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen- expressing cancer
CA3144094A1 (en) 2019-06-21 2020-12-24 Provincial Health Services Authority Radiolabeled compounds targeting the prostate-specific membrane antigen
WO2021177390A1 (ja) 2020-03-04 2021-09-10 日本メジフィジックス株式会社 化合物及び放射性標識化合物
US20230165979A1 (en) * 2020-05-06 2023-06-01 Cornell University Copper-containing theragnostic compositions and methods of use
JP2023552383A (ja) * 2020-12-04 2023-12-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ペプチド受容体放射性核種療法
EP4263509A4 (en) * 2020-12-16 2024-12-04 The University of British Columbia RADIOACTIVELY LABELLED COMPOUNDS FOR TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN
CN114685599A (zh) * 2020-12-30 2022-07-01 南京江原安迪科正电子研究发展有限公司 一种psma靶向抑制剂及放射性核素标记的psma靶向抑制剂、制备方法和用途
CN116940557A (zh) * 2021-03-04 2023-10-24 日本医事物理股份有限公司 化合物及放射性标记化合物
AU2022228911A1 (en) * 2021-03-04 2023-09-21 Kyoto University Compound and radioactive labeling compound
EP4486756A1 (en) * 2022-03-04 2025-01-08 Provincial Health Services Authority Radiolabeled compounds targeting the prostate-specific membrane antigen
WO2024126687A1 (en) * 2022-12-16 2024-06-20 Silence Therapeutics Gmbh Nucleic acids conjugated to an albumin binding moiety
CN118496305A (zh) * 2023-02-16 2024-08-16 无锡诺宇医药科技有限公司 Psma靶向放射性药物及其合成和应用
CN116217505B (zh) * 2023-03-17 2024-10-01 南京医科大学 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0621973D0 (en) * 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
PL3222617T3 (pl) * 2009-03-19 2023-01-02 The Johns Hopkins University Związki do kierunkowania w psma i ich zastosowania
PL2739316T3 (pl) * 2011-08-05 2019-09-30 Molecular Insight Pharmaceuticals, Inc. Radioznakowane inhibitory antygenu błonowego specyficznego dla prostaty
US10011632B2 (en) * 2011-08-22 2018-07-03 Siemens Medical Solutions Usa, Inc. PSMA imaging agents
JP2016537027A (ja) * 2013-11-06 2016-12-01 ソルスティス バイオロジクス,リミティッド ジスルフィド基を有するポリヌクレオチド構築物
CN105849568B (zh) 2013-11-14 2018-05-04 恩多塞特公司 用于正电子发射断层术的化合物
ES2912753T3 (es) * 2014-08-24 2022-05-27 Max Planck Gesellschaft Zur Foerderung Der Wss Método para la producción de ésteres activos marcados con 18F y su aplicación ejemplificada por la preparación de un marcador de PET específico de PSMA
SI3356385T1 (sl) * 2015-09-30 2021-04-30 Deutsches Krebsforschungszentrum 18F-označeni inhibitorji prostatnih membranskih antigenov (PSMA) in njihova uporaba kot slikovno prikazna sredstva za rak prostate
RS62274B1 (sr) * 2016-03-22 2021-09-30 Univ Johns Hopkins Sredstva sa visokim afinitetom za ciljano dejstvo na membranski antigen specifičan za prostatu za endoradioterapiju kancera prostate
AU2017281364B2 (en) * 2016-06-23 2023-06-22 Cornell University Double targeted constructs to affect tumor kill
DE102016122273B4 (de) * 2016-11-18 2018-06-21 Abx Advanced Biochemical Compounds Gmbh Präkursoren für die Radiofluorierung

Similar Documents

Publication Publication Date Title
CN101668547B (zh) 选择缺氧组织的弱碱性2-硝基咪唑递送剂及其应用方法
US8435489B2 (en) Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma
EP1389209B1 (en) Folate mimetics and folate-receptor binding conjugates thereof
US11147889B2 (en) Albumin-binding PSMA inhibitors
US11541133B2 (en) Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes
JP2018058847A5 (enExample)
JP2014510729A5 (enExample)
RU2011146362A (ru) Набор для предварительного таргетинга, способ и средства, используемые в нем
JP2010523599A5 (enExample)
JP2010524965A5 (enExample)
CA3030907A1 (en) Chelated psma inhibitors
DE602004017290D1 (de) Konjugate für medizinische abbildungen umfassend träger, targeting-anteile und kontrastmittel
JP2016528299A5 (enExample)
JP2012504131A5 (enExample)
CA2722858C (en) Substrate based pet imaging agents
JP2018502150A5 (enExample)
JP2009538894A5 (enExample)
Das et al. 177Lu-DOTMP: a viable agent for palliative radiotherapy of painful bone metastasis
JP2013507345A5 (enExample)
Welch et al. Production of non-standard PET radionuclides and the application of radiopharmaceuticals labeled with these nuclides
US20090028791A1 (en) Dichloroacetate Analogs as Imaging Agents
JP2024542261A (ja) 診療に寄与する新規ホウ素リポソーム
JP6263716B2 (ja) 悪性腫瘍のpet診断用トレーサー
JP2018511648A5 (enExample)
Sartor et al. Stromal targeted therapy in bone metastatic prostate cancer: promise delivered